Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Author(s): Andrew Kyle Henderson Robertson, Caterina Fortunata Ramogida, Paul Schaffer, Valery Radchenko*

Journal Name: Current Radiopharmaceuticals

Volume 11 , Issue 3 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: The development of radiopharmaceuticals containing 225Ac for targeted alpha therapy is an active area of academic and commercial research worldwide.

Objectives: Despite promising results from recent clinical trials, 225Ac-radiopharmaceutical development still faces significant challenges that must be overcome to realize the widespread clinical use of 225Ac. Some of these challenges include the limited availability of the isotope, the challenging chemistry required to isolate 225Ac from any co-produced isotopes, and the need for stable targeting systems with high radiolabeling yields.

Results: Here we provide a review of available literature pertaining to these challenges in the 225Acradiopharmaceutical field and also provide insight into how performed and planned efforts at TRIUMF - Canada’s particle accelerator centre - aim to address these issues.

Keywords: Actinium-225, targeted alpha therapy, isotope production, radiochemistry, radiolabeling, TRIUMF.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 21 October, 2018
Page: [156 - 172]
Pages: 17
DOI: 10.2174/1874471011666180416161908

Article Metrics

PDF: 100
HTML: 19